

In the Claims:

1-28. (Canceled).

29. (Presently amended). A modified botulinum toxin type B neurotoxin wherein said modification comprises comprising a tyrosine-based motif Y-x-x-Hy (SEQ ID NO. 23), wherein Y is a tyrosine, x is any amino acid, and Hy is a hydrophobic amino acid, and wherein the modified toxin is structurally different from a wild type neurotoxin.

30. (Presently amended). The modified toxin neurotoxin of claim 29 wherein said Hy is leucine, isoleucine, methionine, alanine, phenylalanine, tryptophan, valine or tyrosine tyrosine-based motif comprises a run of four amino acids, wherein an amino acid comprising an N-terminal end of said run comprises a tyrosine residue and an amino acid comprising a C-terminal end of said run comprises a hydrophobic amino acid.

31-32. (Canceled).

33. (Presently amended). The modified toxin neurotoxin of claim 29 31, wherein Hy is leucine said structural modification includes a tyrosine-based motif with a mutation to one or more amino acids comprising said tyrosine-based motif.

34-68. (Canceled).